CLINICAL TRIAL

Treatment for Cystic Fibrosis

Recruiting · 18+ · All Sexes · Philadelphia, PA

This study is evaluating whether a new therapy may help improve medication and visit compliance, as well as an overall sense of well-being and coping skills for individuals with cystic fibrosis.

See full description

About the trial for Cystic Fibrosis

Eligible Conditions
Cystic Fibrosis · Fibrosis

Treatment Groups

This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Control Group 1
Acceptance and Commitment Therapy adapted for Cystic Fibrosis (ACT with CF)
BEHAVIORAL
Control Group 2
Supportive Psychotherapy (Treatment as Usual Control)
BEHAVIORAL

Eligibility

This trial is for patients born any sex aged 18 and older. There are 4 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Men and women aged 18 and above.
Able to read/understand English.
Diagnosis of cystic fibrosis.
PHQ-9 score > 4 or GAD-7 score > 4.
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 3 months before study, 3 months after study.
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 months before study, 3 months after study.
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 3 months before study, 3 months after study..
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Treatment will improve 4 primary outcomes and 8 secondary outcomes in patients with Cystic Fibrosis. Measurement will happen over the course of Change at baseline (study entry point, before any sessions have been delivered), after 6 weeks of treatment, 3 months after the end of 6 sessions of treatment..

Beck Depression Inventory-II (BDI-II)
CHANGE AT BASELINE (STUDY ENTRY POINT, BEFORE ANY SESSIONS HAVE BEEN DELIVERED), AFTER 6 WEEKS OF TREATMENT, 3 MONTHS AFTER THE END OF 6 SESSIONS OF TREATMENT.
Widely used indicator of the severity of depression.
CHANGE AT BASELINE (STUDY ENTRY POINT, BEFORE ANY SESSIONS HAVE BEEN DELIVERED), AFTER 6 WEEKS OF TREATMENT, 3 MONTHS AFTER THE END OF 6 SESSIONS OF TREATMENT.
Cognitive Fusion Questionnaire (CFQ13)
BEGINNING OF STUDY, AFTER 6 WEEKS, AFTER 3 MONTHS.
Change in cognitive fusion (rigid attachment to one's thoughts as Truth) measures.
BEGINNING OF STUDY, AFTER 6 WEEKS, AFTER 3 MONTHS.
Self-Reported Medication Adherence Questionnaire
BEGINNING OF STUDY, AFTER 6 WEEKS, AFTER 3 MONTHS.
Participant change in medication adherence.
BEGINNING OF STUDY, AFTER 6 WEEKS, AFTER 3 MONTHS.
Patient rated outcomes measures (PRO) Questionnaire.
BEGINNING OF STUDY, AFTER 6 WEEKS, AFTER 3 MONTHS.
Change in patient rated outcomes measures (PRO) including quality of care questionnaire.
BEGINNING OF STUDY, AFTER 6 WEEKS, AFTER 3 MONTHS.
Acceptance and Action Questionnaire (AAQ-II)
BEGINNING OF STUDY, AFTER 6 WEEKS, AFTER 3 MONTHS.
Change in acceptance measures.
BEGINNING OF STUDY, AFTER 6 WEEKS, AFTER 3 MONTHS.
Patient Health Questionnaire 9 (PHQ-9)
CHANGE AT BASELINE (STUDY ENTRY POINT, BEFORE ANY SESSIONS HAVE BEEN DELIVERED), AFTER 6 WEEKS OF TREATMENT, 3 MONTHS AFTER THE END OF 6 SESSIONS OF TREATMENT.
Use as a screening tool to assist the clinician in making the diagnosis of depression and to quantify depression symptoms and monitor severity.
CHANGE AT BASELINE (STUDY ENTRY POINT, BEFORE ANY SESSIONS HAVE BEEN DELIVERED), AFTER 6 WEEKS OF TREATMENT, 3 MONTHS AFTER THE END OF 6 SESSIONS OF TREATMENT.
See More

Who is running the study

Principal Investigator
C. V. O.
C. Virginia O'Hayer, Principal Investigator
Thomas Jefferson University

Patient Q & A Section

Ask a question about the study

Other questions from users

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any geographic restrictions to consider when applying for this trial?

Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.

Will my insurance cover participating in this trial?

In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.

See if you qualify for this trial
Get access to this novel treatment for Cystic Fibrosis by sharing your contact details with the study coordinator.